PP
PHAT icon

PDT Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

PDT Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,922
Closed -$101K – 1027
2022
Q2 		$101K Sell
11,922
-9,278
-44% -$95.4K 0.01% 883
2022
Q1 		$289K Hold
21,200
– – 0.02% 733
2021
Q4 		$417K Buy
21,200
+6,300
+42% +$148K 0.03% 577
2021
Q3 		$478K Hold
14,900
– – 0.03% 489
2021
Q2 		$504K Buy
+14,900
New +$534K 0.03% 512

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PDT Partners's PHAT Position: Q3 2022 in Review

PDT Partners sold out of Phathom Pharmaceuticals (PHAT) in Q3 2022, closing a stake of 11,922 shares — an estimated $101K sold.

PDT Partners first reported a position in PHAT in Q2 2021 and held it in 5 quarters. The position peaked at $504K in Q2 2021. 94 funds tracked by Wall St. Rank hold PHAT as of Q3 2022.

  • PDT Partners reported no remaining Phathom Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • PDT Partners sold 11,922 Phathom Pharmaceuticals shares in Q3 2022, an estimated $101K.
  • PDT Partners first reported a position in Phathom Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • PDT Partners's Phathom Pharmaceuticals position peaked at $504K in Q2 2021.
  • 94 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2022.

Based on PDT Partners's 13F filing for Q3 2022, filed 14 Nov 2022.